48 research outputs found
Imitatio heroica
Get PDFUnter dem Begriff der imitatio heroica lassen sich Formen des Auftretens und der Darstellung historischer Personen zusammenfassen, die sich heroische Figuren zum Vorbild nehmen. Seit der Antike gehört dies zu den häufigsten Formen vor allem, aber nicht nur der Bildnisrepräsentation politisch oder kulturell bedeutender Personen. Der Sammelband Imitatio heroica, Heldenangleichung im Bildnis widmet sich erstmals epochen- und disziplinenübergreifend diesem Phänomen. Dabei wird ein Zeitraum von der Antike bis zum 18. Jahrhundert in den Blick genommen. Ein grundsätzlicher Phänomenaufriss und Fallstudien aus den Bild- und Literaturwissenschaften machen die formalen und semantischen Grundlagen, Bedeutungen und historischen Tiefendimensionen der imitatio heroica anschaulich. In Heldenangleichungen wird das Heroische in seinen je historisch, medial und sozial bedingten Formen erkennbar, vor allem aber im Hinblick auf seine sinnliche Erfahrbarkeit das spezifische Potenzial visueller und habitueller Ausdrucksformen
The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion
Get PDFVirus-Related Serology and in situ Hybridization for the Detection of Virus DNA among Patients with Testicular Cancer
No full textProspective, long-term analysis of quality-of-life during interleukin (IL)-2 immunotherapy
No full textDoes Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study
No full textSu1084 – No Significant Impact of Fructose Consumption on Gut Microbiota Composition in a German Cohort of Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease (NAFLD)
No full textDifferences in Patient Characteristics Among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice at a European High-Volume Center
No full textImpact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies
No full textBackground: To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies for mHSPC.
Material and Methods: Of 213 mHSPC patients diagnosed between 01/2013-12/2020 who subsequently developed metastatic castration resistant prostate cancer (mCRPC), 204 eligible patients were analyzed after having applied exclusion criteria. mHSPC patients were classified into TTCR 24 months and analyzed regarding OS. Moreover, further OS analyses were performed after having developed mCRPC status according to TTCR. Logistic regression models predicted the value of TTCR on OS.
Results: Median follow-up was 34 months. Among 204 mHSPC patients, 41.2% harbored TTCR 24 months. Median age was 67 years and median PSA at prostate cancer diagnosis was 61 ng/ml. No differences in patient characteristics were observed (all p>0.05). According to OS, TTCR 24 months, in that order (p24 months (all p0.05).
Conclusion: Patients with TTCR <12 months are at the highest OS disadvantage in mHSPC. This OS disadvantage persisted even after multivariable adjustment. Interestingly, TTCR stratified analyses did not influence OS in mCRPC patients
